加强肝癌内科队伍建设,重视肝癌内科规范化和个性化诊疗决策

[1]

Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.

[2]

Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.

[3]

Qiao Min, Zhao Yijian,Z hang Jianqiao,et al. Efficacy of TACE and radiofrequency ablation combination in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 119-122.

[4]

[5]

Han Pengwei, Wang Huming, Zhao Tianyong. Clinical feature and prognostic factors of primary liver cancer patients with serum AFP negative after TACE [J]. Journal of Practical Hepatology, 2020, 23(5): 715-718.

[6]

Zhou Binbin,Sun Yaochen,Huang Haifan, et al.. Evaluation of functional magnetic resonance imaging in patients with hepatocellular carcinoma after TACE [J]. Journal of Practical Hepatology, 2020, 23(5): 723-726.

[7]

Liu Xu, Hu Yuchang, Cheng Lu, et al.. Clinicopathological manifestation of primary liver adenosquamous carcinoma: An analysis of six cases [J]. Journal of Practical Hepatology, 2020, 23(5): 727-730.

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

PDF (PC)